About the APPRAISE-1 StudyThe study was a double-blind, placebo-controlled, dose-ranging study to evaluating the safety and efficacy of apixaban over a 26 – week treatment period in 1715 patients with acute coronary syndrome . All patients received aspirin? 165 mg / day. Left to use of clopidogrel in the discretion of the physician www.generilevitra.com http://www.generilevitra.com . The primary endpoint of the the trial was incidence of ISTH-defined severe bleeding and clinically relevant non-major bleeding. The composite efficacy endpoint was the time from patient randomization to the first occurrence of a combination of heart – cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, severe recurrent ischemia and non – hemorrhagic stroke.
Apixaban being developed by the being developed by the two companies, is an oral, highly selective factor Xa inhibitor, a new class of agents with therapeutic potential to prevent and treat blood clots in the veins and arteries.
, for further info about American Academy of Neurology.